Company Overview
Snapshot
Founded in June 2012 by Prof. Yechezkel Barenholz and Avi Molcho, Ayana Pharma operates with 11–50 employees. The company has secured funding from 2 investors across one funding round. A significant milestone occurred in February 2022 when its cancer drug, Doxil, returned to Earth after being tested on the International Space Station to evaluate its efficacy in microgravity.
Business overview
Ayana Pharma specializes in developing liposome-based treatments for cancer, leveraging the benefits of the anticancer drug Doxil. This FDA-approved liposomal nanodrug has been utilized in treating various conditions, including ovarian cancer, metastatic breast cancer, AIDS-related Kaposis sarcoma, and multiple myeloma. The company aims to expand Doxil's treatment applications and enhance its efficacy and availability, serving the pharmaceuticals, healthcare, and life sciences markets.
Strategic signal
In February 2022, Ayana Pharma's cancer drug, Doxil, completed an experiment on the International Space Station (ISS) to assess its performance in microgravity. This initiative, conducted in partnership with SpacePharma, signals Ayana Pharma's commitment to exploring novel environments for drug development and potentially unlocking new therapeutic pathways for cancer treatment, indicating a forward-looking approach to innovation in oncology.
Log in to access full profile ›Company Intelligence Q&A
- What is Ayana Pharma's core focus?
- Ayana Pharma focuses on developing liposome-based treatments for cancer, utilizing the anticancer drug Doxil to address various conditions such as ovarian cancer, metastatic breast cancer, AIDS-related Kaposis sarcoma, and multiple myeloma.
- When was Ayana Pharma founded and by whom?
- Ayana Pharma was founded in June 2012 by Prof. Yechezkel Barenholz and Avi Molcho.
- What was the purpose of sending Doxil to the International Space Station?
- In December 2021, Ayana Pharma's cancer treatment drug, Doxil, was launched to the International Space Station as part of a SpaceX mission. The experiment aimed to test how Doxil would behave in zero-gravity conditions and understand its effectiveness in a microgravity environment.
- What were the results of the microgravity experiment with Doxil?
- In February 2022, the Israeli cancer drug Doxil returned to Earth after being tested on the International Space Station. The inventor, Prof. Yehezkel Bernholtz, is analyzing the results to determine if treating cancer patients in space-like conditions could offer benefits.
- Which investors have participated in Ayana Pharma's funding rounds?
- Ayana Pharma has secured funding from investors including Integra Holdings.